NeoPhore Appoints Michael Shih as Chief Executive Officer
NeoPhore Limited, a pioneering small molecule neoantigen immuno-oncology company, has announced the exciting appointment of Michael Shih as its Chief Executive Officer (CEO) and member of the Board of Directors. This strategic move is effective immediately, positioning the company for significant growth in the healthcare sector.
Leadership Experience of Michael Shih
Michael Shih brings nearly two decades of extensive experience in corporate development in the pharmaceutical and biotechnology fields. His prior role was as Vice President of Corporate Development at Kite Pharma. In this eminent position, he successfully led various business development initiatives that heightened the company's profile within the industry.
Before his tenure at Kite Pharma, Michael served as the Senior Vice President and Head of Business Development at Biogen. His team excelled in sourcing, structuring, and executing strategic collaborations, as well as mergers and acquisitions that greatly benefited the organization. His remarkable career also includes significant roles at Sanofi as Vice President and Head of Global Transactions, and positions at Epizyme, Forest Laboratories, and Eisai.
Exciting Prospects Ahead for NeoPhore
Robert James, Chairman of the Board at NeoPhore, expressed his enthusiasm regarding Michael's appointment. He emphasized that Michael joins at a pivotal moment in NeoPhore's evolution following a robust Series B financing round, which received backing from Bristol Myers Squibb. This financial boost, combined with Michael's vast experience, is expected to enhance NeoPhore's trajectory towards becoming a clinical entity.
In his remarks, Michael Shih highlighted NeoPhore's innovative strategy targeting the MMR (mismatch repair) pathway. He is optimistic about the potential to make strides in cancer treatment and mentioned his eagerness to work collaboratively with the adept NeoPhore team, who share a commitment to advancing the company's promising pipeline.
NeoPhore's Drug Development Strategy
NeoPhore is diligently developing a range of validated, first-in-class small molecule drugs aimed at proteins across the MMR pathway. The ultimate goal is to enhance the effectiveness and durability of groundbreaking immunotherapies that address cancer. Michael’s leadership as CEO comes at a fortuitous time as the company finalizes its oversubscribed Series B funding round. This development significantly strengthens NeoPhore's ability to implement its growth strategies and optimize its drug pipeline potential.
About NeoPhore
NeoPhore is dedicated to the discovery and advancement of innovative small molecule therapies for cancer treatment, primarily focusing on stimulating the immune system. By generating cancer neoantigens in tumors, the company aims to empower the immune response to overcome the natural defenses cancer poses. Their targeted approach involves the DNA mismatch repair (MMR) pathway, known for its role in generating neoantigens and fostering immunity against various cancers.
The company originated as a spin-out from the University of Turin and PhoreMost Ltd, backed by the CRT Pioneer Fund. NeoPhore's mission is to develop next-generation immuno-oncology therapeutics, striving to elevate clinical outcomes for patients battling cancer.
Frequently Asked Questions
Who is the new CEO of NeoPhore?
The new CEO is Michael Shih, who brings extensive experience from the pharmaceutical and biotech sectors.
What is NeoPhore's main focus?
NeoPhore focuses on developing novel small molecule therapies that stimulate the immune system to treat cancer.
What has motivated NeoPhore's recent growth?
The company raised significant funding through an oversubscribed Series B financing round, allowing for accelerated development of its drug pipeline.
How does NeoPhore's strategy target cancer?
NeoPhore's approach involves targeting the MMR pathway to enhance the effectiveness of immunotherapies in cancer treatment.
What are NeoPhore's origins?
NeoPhore was spun out from the University of Turin and PhoreMost Ltd, aided by the CRT Pioneer Fund.
